Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients

Table 3 Univariate analysis of overall survival in all patients and in patients with normal pretreatment serum carcinoembryonic antigen

Variable	No. of patients	2-yr survival rate (%)	Median survival (mo)	P value
All patients
Pathological T staging				0.001
T0	7	86	52
T3	205	52	37
T4	16	36	27
Lymph node metastasis				0.001
0	15	79	48
0 < r ≤ 0.1	37	68	31
0.1 < r ≤ 0.3	67	42	32
r > 0.3	109	50	33
Chemotherapy				0.029
Adjuvant	168	50	35
Perioperative	60	58	41
Normal-CEA patients
Pathological T staging				0.001
T0	6	83	50
T3	156	50	35
T4	11	39	17
Lymph node metastasis				0.002
0	12	74	44
0 < r ≤ 0.1	29	70	45
0.1 < r ≤ 0.3	50	38	26
r > 0.3	82	49	33
Chemotherapy				0.024
Adjuvant	130	48	34
Perioperative	43	59	43

CEA: Carcinoembryonic antigen.